Department of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany.
Int J Mol Sci. 2022 Dec 16;23(24):16059. doi: 10.3390/ijms232416059.
Endothelial cells are a critical target of the soluble Fms-like tyrosine kinase-1 (sFlt-1), a soluble factor increased in different diseases with varying degrees of renal impairment and endothelial dysfunction, including chronic kidney disease (CKD). Although the mechanisms underlying endothelial dysfunction are multifactorial and complex, herein, we investigated the damaging effects of sFlt-1 on structural and functional changes in endothelial cells. Our results evidenced that sera from patients with CKD stiffen the endothelial cell cortex in vitro, an effect correlated with sFlt-1 levels and prevented by sFlt-1 neutralization. Besides, we could show that recombinant sFlt-1 leads to endothelial stiffening in vitro and in vivo. This was accompanied by cytoskeleton reorganization and changes in the endothelial barrier function, as observed by increased actin polymerization and endothelial cell permeability, respectively. These results depended on the activation of the p38 MAPK and were blocked by the specific inhibitor SB203580. However, sFlt-1 only minimally affected the expression of stiffness-sensitive genes. These findings bring new insight into the mechanism of action of sFlt-1 and its biological effects that cannot be exclusively ascribed to the regulation of angiogenesis.
内皮细胞是可溶性 Fms 样酪氨酸激酶-1(sFlt-1)的一个关键靶点,sFlt-1 是一种可溶性因子,在不同程度肾功能损害和内皮功能障碍的疾病中增加,包括慢性肾脏病(CKD)。虽然内皮功能障碍的机制是多因素和复杂的,但在这里,我们研究了 sFlt-1 对内皮细胞结构和功能变化的破坏作用。我们的结果表明,CKD 患者的血清在体外使内皮细胞皮质变硬,这一效应与 sFlt-1 水平相关,并可通过中和 sFlt-1 来预防。此外,我们可以证明重组 sFlt-1 导致体外和体内的内皮僵硬。这伴随着细胞骨架的重组和内皮屏障功能的变化,分别表现为肌动蛋白聚合的增加和内皮细胞通透性的增加。这些结果取决于 p38 MAPK 的激活,并被特异性抑制剂 SB203580 阻断。然而,sFlt-1 对僵硬敏感基因的表达仅有微小的影响。这些发现为 sFlt-1 的作用机制及其生物学效应提供了新的见解,这些效应不能仅仅归因于血管生成的调节。